Policy & Regulation
Starpharma and MSD sign DEP(R) Research Agreement
11 August 2022 -

Starpharma, an Australia-based biotechnology company, announced on Wednesday that it has signed a new DEP(R) Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, New Jersey, USA.

This new DEP program will generate and evaluate additional DEP Antibody Drug Conjugates (ADCs). This new agreement follows an earlier DEP ADC agreement that Starpharma signed with MSD in February 2021, as well as an expanded DEP Research Agreement with another large US biopharmaceutical company in June 2022.

The company's DEP(R) ADCs have the capability to overcome the limitation of relatively low drug loading that is a feature of first-generation ADCs.